{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-074514","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.772343+00:00","generated_at":"2026-05-17T19:39:09.476316+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"BioXcel announces publication of non-clinical study on dexmedetomidine in Frontiers in Pharmacology","bullets":["Study shows dexmedetomidine potently and reversibly regulates stress-mediated behaviors.","Dexmedetomidine exhibited higher in vitro potency than clonidine, lofexidine, or guanfacine.","Mitigated responses to acute and repeated stress after both acute and repeated dosing, with no loss of effect.","No withdrawal effects; no impact on motor function or cognition vs. diazepam or scopolamine.","Results support BXCL-501's potential for stress-related disorders beyond acute agitation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-074514","json":"https://secwatch.observer/filing/0001104659-25-074514.json","markdown":"https://secwatch.observer/filing/0001104659-25-074514.md","text":"https://secwatch.observer/filing/0001104659-25-074514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925074514/0001104659-25-074514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925074514/tm2522638d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:39:09.476316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}